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This is a de novo drug design study that aimed to create novel structures based on the alkaloid 
Huperzine A, capable of inhibiting the acetylcholinesterase (AChE) enzyme ligand binding pocket 
(AChE_LBP) for the management of Alzheimer’s disease. The X-ray crystallographic model of the 
Torpedo Californica AChE complexed to Huperzine A was identified from the Protein Data Bank (PDB ID 
1VOT). Molecular visualisation and modelling was carried out using SYBYL
®
 1.2, in silico predicted 
ligand binding affinity (LBA) was quantified using XSCORE_V1.3 and de novo drug design was carried 
out using LIGBUILDER®V1.2. Two seed structures were constructed in SYBYL
®
 1.2 according to a 
methodology that took into account the relationship between molecular structure and biological activity 
as described in the literature. Based on SAR data derived from Huperzine A, the points considered to be 
critical for binding were retained in each seed and planted into the AChE_LBP with growth being 
allowed according to defined parameters of LIGBUILDER®V1.2. The implication of this study 
consequently is that novel structures compliant to Lipinski’s Rule of 5 may be promoted to second level 
drug design which could lead to identification of novel AChE inhibitors with better potency and a low 
side effect profile.  
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INTRODUCTION 
 
Alzheimer's disease is the most common cause of 
dementia (Akhondzadeh and Abbasi, 2006)  
characterised by the build-up in the brain of protein rich 
plaques and leading to decreased cerebral nerve cell 
connectivity culminating in the death of nerve cells and 
loss of brain tissue (Wang et al., 2006a). It is also 
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Figure 1. Huperzine A onto its pharmacophore shown in beads 
rendered in Chimera
®
v.1.7. 
 
 
 
 
 
Figure 2. Huperzine A key interaction sites rendered in 
Chimera
®
 v.1.7 based on the coordinates of PDB ID 1VOT 
(Raves et al., 1997). 
 
 
 
 
associated with decreased acetylcholine (Ach) levels, 
due to the fact that this is broken down at a higher than 
average rate by the acetylcholinesterase (AChE).  
This also contributes to incomplete transmission of nerve 
impulses (Picoulin, 2002). 
The naturally occurring alkaloid Huperzine A has been 
shown to be a potent inhibitor of the transport of choline 
through cholinesterase inhibition consequently resulting 
in an increase in ACh. AChE inhibition also results in a 
slower rate of breakdown of acetylcholine and in nerve 
impulses of strength and duration consequently 
enhancing cerebral performance (Zangara, 2003). 
In this study, an analysis of the binding modality of 
Huperzine A within the AChE Ligand Binding Pocket and 
the use of the Huperzine A scaffold to generate analog 
series of lead molecules for further optimisation using a 
static algorithm were reported. 
 
 
METHODOLOGY 
 
Molecular modelling 
 
X-ray crystallographic deposition 1VOT describing the bound co-
ordinates of the Torpedo Californica AChE bound to the nootropic 
alkaloid Huperzine A was identified from the Protein Data Bank and 
used as a template for this study (Raves et al., 1997). 
Molecular modelling was carried out in Sybyl®-X, Ligand Binding 
Affinity (LBA) was quantified in X-Scorev1.2, and de novo ligand 
generation was carried out using LigBuilderv2.0. VMD® v.1.9  
(Humphrey et al., 1996) and Chimera® v.1.7 were used for image 
generation. 
Protein Data Bank crystallographic deposition 1VOT was then 
read into Sybyl®-X and all water molecules at a distance ≥5Å from 
the Ligand Binding Pocket were removed. The bound ligand, 
Huperzine A was extracted from the AChE Ligand Binding Pocket. 
The now apo-AChE and the extracted ligand were saved in PDB 
and mol2 format, respectively. 
 
 
Quantifying the binding affinity (pKd) of huperzine A for the 
AChE 
 
The apo-AChE (saved in pdb format) and the extracted ligand 
(saved in mol2 format) were used as input files for X-Score®v1.2, 
which quantified, based on atomic interactions, the affinity(pKd)  of 
the bioactive conformer of Huperzine A for its co-crystallised Ligand 
Binding Pocket (Wang et al., 1998). This procedure was considered 
as vital in the establishment of a baseline affinity against which that 
of the de novo generated Huperzine A analogs could be compared. 
 
 
AChE ligand binding pocket mapping 
 
The POCKET module of LIGBUILDER® v2.0 (Wang et al., 2000) 
was used to generate a pharmacophore and a 3-Dimensional map 
of the AChE Ligand Binding Pocket as circumscribed around the 
bioactive conformation of Huperzine A. Both the general 
pharmacophoric structure and the 3-Dimensional map of the AChE 
Ligand Binding Pocket were colour coded by atom type, with 
hydrogen bond donors and acceptors being coloured blue and red, 
respectively and with hydrophobic sites being coloured cyan. These 
are described in Figures 1 and 2, respectively. 
The output file in each case was in pdb format and could be
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Table 1. The 2-dimensional and 3-dimensional structure of Huperzine A as rendered in Symyx
® 
Draw 4.0 and VMD
® 
v1.9, along with its 
predicted in silico ligand binding affinity to its cognate receptor 1VOT, as calculated in X-Score
®
 v1.3. 
 
2-Dimensional Structure 3-Dimensional Structure 
Predicted in silico LBA within cognate 
receptor 
Huperzine A within 1VOT 
 
 
HPScore –log(Kd) = 6.41 
HMScore –log(Kd) = 6.41 
HSScore –log(Kd) = 6.54 
Predicted average –log(Kd) = 6.45 
Predicted binding energy =  -8.80 kcal/mol 
 
 
 
visualised in VMD® v.1.9 (Humphrey et al., 1996) and Chimera® 
v.1.7. This process was important because it established the 
pharmacophoric space available for de novo ligand construction, as 
well as the general pharmacophoric structure to which all the de 
novo generated ligands must necessarily comply for efficient 
binding.     
 
 
Seed structure construction 
 
A seed structure is essentially a molecular scaffold that is capable 
of sustaining molecular growth at user directed pre-designated 
growing sites. For this study, two seed structures were constructed 
in Sybyl®-X according to a methodology that took into account the 
relationship between molecular structure and biological activity as 
described in the literature. Seed A was created by removing the 
methyl group at the 15-position and the carbon group at the 14-
position thereby opening the last ring of Huperzine A.  
Seed B was created by removing the fused cyclic rings and 
retaining solely the aromatic ring bearing the carbonyl group and 
two methyl groups at the 6 and 12 positions. The carbonyl group 
was retained in both seeds because the pyridone oxygen forms a 
strong hydrogen bond with a protein residue of the ligand binding 
pocket. In Seed A, atoms 8 and 13 were designated as growing 
sites (H.spc) whereas in Seed B, atoms 6 and 12 were designated 
as growing sites (H.spc).  
 
 
de Novo ligand design 
 
The modelled seed structures were successively docked into the 
AChE Ligand Binding Pocket 3-Dimensional map, with which 
molecular growth was sustained according to the generic algorithm 
embedded in the GROW module of LigBuilder®V2.0. 
The PROCESS module of LigBuilder®V2.0 was used to organise 
the de novo generated structured into families based on 
pharmacophoric similarity, and ranked  in  order  of  Ligand  Binding  
Affinity (pKd). 
 
 
RESULTS 
 
The in silico LBA (pKd) of Huperzine A to its cognate 
receptor was predicted to be 6.45 as shown in Table 1. 
The algorithm embedded in the PROCESS module of 
LIGBUILDER
®
V2.0. This process resulted in 200 and 600 
molecules to be generated from Seeds A and B, 
respectively. These de novo structures were divided into 
a number of families whose in silico affinity (pKd), 
molecular weight (Daltons/Da) and logP are displayed in 
Figures 3 to 8, respectively. Each molecular structure 
was assessed for Lipinski rule of 5 (predictors of in vivo 
bioavailability) rule compliance (Lipinski et al., 1997). The 
pKd for the de novo molecules ranged from 6.30 to 10, 
while molecular weight ranged from 300 to 526 and the 
LogP ranged from 3 to 5.99. A summary of all the values 
in each seed may be seen in Table 2. 
 
 
DISCUSSION 
 
All 15 molecules chosen from Seed A and all 45 
molecules chosen from Seed B were Lipinski rule 
compliant. In an ideal scenario, the molecules with the 
highest LBA (pKd) would also have the lowest LBE (kcal 
mol
-1
). The best molecule from the top 15 molecules 
chosen from Seed A is molecule number 6 having a pKd 
of 8.82 and a LBE of 126.999 kcal mol
-1
. Moreover, the
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Figure 3. A graph showing the pKd (in silico) for the 200 de novo designed ligands from Seed A; the 17 different colours imply the 17 
family series. 
 
 
 
best molecule from the top 45 molecules chosen from 
Seed B is molecule number 3 having a pKd of 9.37 and a 
LBE of 45.796 kcal mol
-1
. The binding poses of molecules 
6 and 4 are superimposed onto the bound co-ordinates of 
Huperzine A as shown in Figures 9 and 10. 
From this de novo study, the following relationships 
between structure and activity have been identified:  
1) Ligands having two  aromatic  rings  connected  by  an 
aliphatic chain have a high LBA (pKd) and a low LBE 
(kcal mol
-1
). This was evident from molecules generated 
from Seed B. 
2) Molecules with an aromatic ring directly attached to a 
pyridine ring bearing a negatively charged oxygen atom 
have been observed to have a lower LBA (pKd) and a 
higher LBE (kcal mol
-1
). This was apparent from ligands 
generated from Seed A. 
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Figure 4. A graph showing the pKd (in silico) for the 600 de novo designed ligands from Seed B; the 35 different colours imply the 35 family 
series. 
 
 
(3) Ligands with lateral branching ending in an acidic 
group (specifically the carboxyl group) from the pyridine 
bearing the carbonyl group have a higher LBA (pKd) than 
those which did not have an acidic group.  
(4) Molecules having an aromatic ring linked to a pyridine 
bearing a negatively charged oxygen group exhibited a 
lower LBA (pKd) than molecules not having a negatively 
charged oxygen group connected to the pyridine ring. 
(5) Ligands having an aromatic ring bearing a carboxylate 
anion had  a  higher  LBA  (pKd)  than  those  without  the  
carboxylate anion. 
The implication of this study is that all the novel 
molecules sampled from both seeds which are also 
compliant to Lipinski’s Rule of 5, are candidates for 
subsequent iterative rounds of rational drug design and in 
vitro validation.  
The best two ligands identified from this study may be 
considered as viable leads for further optimisation 
studies. Comparative molecular dynamics studies could 
shed further light on the way that these ligands interact
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Figure 5. A graph showing the molecular weight for the 200 de novo designed ligands from Seed A. All ligands have a molecular 
weight of less than 500 and therefore are Lipinski rule of 5 compliant with respect to molecular weight only. 
 
 
 
Table 2. Summary of important parameters of all the de novo molecules generated within LigBuilder
®
 v2.0. 
 
AChE_LBP Seed A Seed B 
Total number of molecules 200 600 
No. of families 17 35 
Maximum number of molecules per family 51 125 
Minimum number of molecules per family 1 1 
Maximum pKd 8.92 10 
Minimum pKd 6.30 8.47 
Maximum molecular weight 438 526 
Minimum molecular weight 300 326 
Maximum LogP 5.43 5.99 
Minimum LogP 3 3.01 
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Figure 6. A graph showing the molecular weight for the 600 de novo designed ligands from Seed B. The red colour indicates a molecular 
weight of less than 500 and therefore these ligands are Lipinski rule of 5 compliant with respect to molecular weight only. The yellow colour 
indicates a molecular weight exceeding 500 and thus such ligands are not Lipinski rule of 5 compliant with respect to molecular weight only.  
 
 
 
with the AChE Ligand Binding Pocket relative to 
Huperzine A, with Principal Component Analysis 
indicating the most significant ligand driven 
conformational changes which could be exploited in in 
silico attempts to identify novel entities with higher 
LBAs(pKd) and lower LBEs (kcal mol
-1
).  This  could  lead  
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Figure 7. A graph showing the value of LogP for the 200 de novo ligands generated from Seed A. The yellow colour indicates a value of more 
than 5 and therefore such molecules are non-compliant with the Lipinski Rule of 5 with respect to LogP only. 
 
 
 
to the identification of innovative AChE inhibitors with 
better potency and a low side effect profile. AChE 
inhibitors will continue to be developed, because this 
class of drugs has shown promise in symptomatic
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Figure 8. A graph showing the value of LogP for the 600 de novo ligands generated from Seed B. The yellow colour 
indicates a value of more than 5 and therefore such molecules are non-compliant with the Lipinski Rule of 5 with 
respect to LogP only. 
 
 
 
 
 
Figure 9. Superimposition of Molecule 6 (shown in light blue and white) 
onto Huperzine A (shown according to molecular type). 
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Figure 10. Superimposition of Molecule 4 (shown in light blue and white) 
onto Huperzine A (shown according to molecular type). 
 
 
 
therapy (Mehta et al., 2011). 
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